U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H27NO
Molecular Weight 321.4559
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHYBENZTROPINE

SMILES

CCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C3=CC=CC=C3)C4=CC=CC=C4

InChI

InChIKey=PHTMLLGDZBZXMW-AERCQKQUSA-N
InChI=1S/C22H27NO/c1-2-23-19-13-14-20(23)16-21(15-19)24-22(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12,19-22H,2,13-16H2,1H3/t19-,20+,21+

HIDE SMILES / InChI

Description

Ethybenzatropine (Ponalid) is an anticholinergic and antihistaminergic drug. It was used as an antiparkinsonian agent. A significant increase in the duration of action of levodopa-induced improvement in parkinsonian symptoms was observed following the administration of ethybenzatropine. Ethybenzatropine also improved, or tended to improve the duration and seventy of onset and end-of-dose levodopa-induced dyskinesias. Thus when levodopa is administered together with etybenzatropine, its length of action on parkinsonian symptoms is prolonged.

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
Nine patients with Parkinson’s disease: Levodopa was given orally together with a peripheral DOPA-decarboxylase inhibitor at the usual effective morning dosage for each patient. The same dose of levodopa was administered the next day in addition to ethybenzatropine, 5 mg given i.v. Ethybenzatropine was administered between 0 and 15 min after the first dose of levodopa
Route of Administration: Intravenous